199 / 206
events. Implications for prevention / D.W. Bates [et al.] // JAMA, 1995, 274,
29-34.
158. Inman, W.H.W. Requirements for risk benefit assessment of
drugs before withdrawal / W.H.W. Inman // B.I.R.A. J., 1986, 5 (2), 11-15.
159. Kubota, K. Prescription-event monitoring in Japan (J-PEM) / K.
Kubota // Drug Saf. 2002, 25(6), 441-444.
160. Lazarou, J. Incidence of adverse drug reactions in hospitalized
patients / J.Lazarou, B.H.Pomeranz, P.N. Corey //JAMA, 1998; №279:1200
1205.
161. Leape, L.L. The nature of adverse events in hospitalized patients.
Results of the Harvard Medical Practice Study II, N. / L.L. Leape, T.A.
Brennan, N. Laird // Engl. J. Med., 1991, 324, 377-384.
162. Lepori, V. Adverse internal medicine drug effects at hospital
admission / V. Lepori, A. Perren, C. Marone // Schweiz Med Wochenschr,
1999, 19, 129 (24), 915-922.
163. Lindquist, R. Understanding and preventing adverse drug events /
R. Lindquist, L.M. Gersema // AACN Clin. Issues, 1998, 9(1), 119-128.
164. Lindquist, R. Understanding and preventing adverse drug events,
AACN / R. Lindquist, L.M. Gersema // Clin. Issues, 1998, 9(1), 119-128.
165. McBride, W.G. Thalidomide and congenital abnormalities / W.G.
McBride // Lancet, 1961. - N 2. - p.1358.
166. Medication Errors at the Administration Stage in an Intensive
Care Unit / E. Tissot [et al.] // Intensive Care. Med., 1999, 25(4), 353-359.
167. Medication errors in a pediatric department / Olsen P.M. [et al.].
Ugeskr Laeger, 1997, 14, 159(16), 2392-2395.
168. Moore, N.D. Serious ADR in a department of internal medicine /
N.D. Moore, D. Lecaintre, C. Nobet // Pharmacoepidemiology and Drug
Safety, 1995, 4, 74.
169. Newby, D. An introduction to ADRs / D. Newby // Curr. Therap.,
- 195 -
195